Key facts
- It has raised $1.4M across 1 recorded rounds; the latest was Seed Round ($618K) in Nov 2018.
- Notable investors include National Institutes of Health, Impact Foundation, Discovery to Product, Lawrence University, Wisconsin Technology Innovation Initiative.
- Cellular Logistics has filed 7 Form Ds with the SEC since 2016, most recently Apr 2025 ($50K sold to 2 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Cellular Logistics
Funding rounds
1 roundsAbout Cellular Logistics
Developer of an acellular biomaterial designed to significantly increase cell survival rates and retention of regenerative medicine therapeutics. The company's biomaterial is a stand-alone therapeutic for cardiac and tissue regeneration applications and also for providing a cell delivery mechanism for regenerative medicine therapeutics, enabling patients to avail of improved post-injection cell retention therapeutics.
- Sector
- Healthcare
- HQ
- Madison, WI, United States
- Founded
- 2016
- Employees
- 6
- Website
- cellogistics.com/
- Ownership
- Privately Held (backing)
Cellular Logistics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellular Logistics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellular Logistics in its N-PORT filings yet. We sweep new filings monthly.